I Sriprasert1,2, H N Hodis1,3,4, B Bernick5, S Mirkin5, W J Mack1,4. 1. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 2. Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 3. Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 4. Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 5. TherapeuticsMD, Boca Raton, FL, USA.
Abstract
Objective: This study evaluated associations of estradiol (E2) dose and serum E2 levels with coagulation/anti-coagulation measures in early (<6 years) compared with late (≥10 years) postmenopausal women. Methods:Postmenopausal women from the REPLENISH trial tested four formulations of oral combined E2 and progesterone compared with placebo. Mixed-effects linear models tested the association of E2 dose and serum E2 levels with the prothrombin time (PT), the activated partial thromboplastin time (APTT), antithrombin (ATHRM), fibrinogen (FIBRINO), protein C (PROTC), and protein S (PROTS), assessed five times over 12 months. Results:Among 1215 early and 297 late postmenopausal women, the E2 dose was statistically significantly inversely associated with the APTT in early postmenopause, PROTC in late postmenopause, and with the PT, ATHRM, and PROTS in both groups. Serum E2 levels were statistically significantly inversely associated with the APTT, PROTS, and FIBRINO in early postmenopause, the PT in late postmenopause, and ATHRM and PROTC in both groups. With longer time since menopause, the inverse E2 dose effect and serum E2 effects became stronger. Conclusion:Increasing E2 dose and serum E2 levels were associated with changes in coagulation/anti-coagulation measures. The associations were stronger among women ≥10 years since menopause when initiating E2. The timing of E2 therapy, E2 dose, and serum E2 levels relative to time since menopause may modify the venous thromboembolism risk.
RCT Entities:
Objective: This study evaluated associations of estradiol (E2) dose and serum E2 levels with coagulation/anti-coagulation measures in early (<6 years) compared with late (≥10 years) postmenopausal women. Methods: Postmenopausal women from the REPLENISH trial tested four formulations of oral combined E2 and progesterone compared with placebo. Mixed-effects linear models tested the association of E2 dose and serum E2 levels with the prothrombin time (PT), the activated partial thromboplastin time (APTT), antithrombin (ATHRM), fibrinogen (FIBRINO), protein C (PROTC), and protein S (PROTS), assessed five times over 12 months. Results: Among 1215 early and 297 late postmenopausal women, the E2 dose was statistically significantly inversely associated with the APTT in early postmenopause, PROTC in late postmenopause, and with the PT, ATHRM, and PROTS in both groups. Serum E2 levels were statistically significantly inversely associated with the APTT, PROTS, and FIBRINO in early postmenopause, the PT in late postmenopause, and ATHRM and PROTC in both groups. With longer time since menopause, the inverse E2 dose effect and serum E2 effects became stronger. Conclusion: Increasing E2 dose and serum E2 levels were associated with changes in coagulation/anti-coagulation measures. The associations were stronger among women ≥10 years since menopause when initiating E2. The timing of E2 therapy, E2 dose, and serum E2 levels relative to time since menopause may modify the venous thromboembolism risk.
Entities:
Keywords:
Estradiol; hormones; menopause; thrombosis; women
Authors: Rogerio A Lobo; David F Archer; Risa Kagan; Andrew M Kaunitz; Ginger D Constantine; James H Pickar; Shelli Graham; Brian Bernick; Sebastian Mirkin Journal: Obstet Gynecol Date: 2018-07 Impact factor: 7.661
Authors: J K Williams; M S Anthony; E K Honoré; D M Herrington; T M Morgan; T C Register; T B Clarkson Journal: Arterioscler Thromb Vasc Biol Date: 1995-07 Impact factor: 8.311
Authors: D Grady; N K Wenger; D Herrington; S Khan; C Furberg; D Hunninghake; E Vittinghoff; S Hulley Journal: Ann Intern Med Date: 2000-05-02 Impact factor: 25.391
Authors: Henry M P Boardman; Louise Hartley; Anne Eisinga; Caroline Main; Marta Roqué i Figuls; Xavier Bonfill Cosp; Rafael Gabriel Sanchez; Beatrice Knight Journal: Cochrane Database Syst Rev Date: 2015-03-10
Authors: Howard N Hodis; Wendy J Mack; Victor W Henderson; Donna Shoupe; Matthew J Budoff; Juliana Hwang-Levine; Yanjie Li; Mei Feng; Laurie Dustin; Naoko Kono; Frank Z Stanczyk; Robert H Selzer; Stanley P Azen Journal: N Engl J Med Date: 2016-03-31 Impact factor: 91.245